# West Pharmaceutical Services Inc. (WST) fundamentals

Data as of 2026-09-08. NYSE, United States. Sector: Healthcare / Health Care Equipment & Supplies. Price $339.97, market value $23.9 billion.

## Valuation
- **P/E (trailing): 43.5×** (5-yr avg 43.4×, 3-yr avg 44.5×). West Pharmaceutical Services Inc. trades at 43.5× trailing earnings, close to its own five-year average of 43.4×. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 34.1×, lower than trailing, so analysts expect earnings to grow.
- **Price / sales: 7.2×**. Each dollar of revenue is priced at 7.2×.
- **Price / book: 8.0×**. The shares trade at 8.0× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **EV / EBITDA: 27.1×**. Enterprise value is 27.1× operating earnings before depreciation, the multiple that ignores how the company is financed; above 20× is demanding.
- **Free-cash-flow yield: 1.8%** (5-yr avg 1.7%). Free cash flow equals 1.8% of the market value, in line with its five-year average of 1.7%.
- **Earnings yield: 2.3%**. The inverse of the P/E: 2.3% of the price is earned each year.

## Profitability
- **Gross margin: 36.8%**. West Pharmaceutical Services Inc. keeps 36.8% of revenue after the direct cost of what it sells.
- **Operating margin: 20.5%**. 20.5% of revenue is left after running the business, a healthy level in most sectors.
- **Net margin: 16.1%**. 16.1% of each dollar of sales reaches the bottom line.
- **Return on equity: 15.5%**. 15.5% on shareholders' equity is solid.
- **Return on invested capital: 20.8%**. Return on all capital, debt included, is 20.8%: comfortably above what that capital costs.
- **Return on assets: 13.2%**. Each dollar of assets produces 13.2% of profit.

## Growth
- **Revenue growth (1 yr): 6.3%** (3-yr 2.1%/yr, 5-yr 7.4%/yr). Revenue grew 6.3% over the last year, against 7.4% a year compounded over five years.
- **EPS growth (1 yr): 1.5%** (3-yr -4.2%/yr, 5-yr 8.2%/yr). Earnings per share rose 1.5%, roughly in step with revenue.
- **Free-cash-flow growth (3 yr): 2.2%/yr**. Free cash flow has compounded at 2.2% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 0.06**. Debt is 0.06 times equity: a conservative balance sheet.
- **Net debt / EBITDA: net cash**. West Pharmaceutical Services Inc. holds more cash than debt.
- **Altman Z-score: 15.34**. A Z-score of 15.34 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend yield: 0.26%** ($0.87 per share, trailing). West Pharmaceutical Services Inc. yields 0.26%, a modest yield more typical of a growth-oriented payer.
- **Payout ratio: 12%** (14% of free cash flow). 12% of earnings goes out as dividends, leaving room to keep raising it.
- **Consecutive years of increases: 26**. 26 straight years of increases (the data covers 26 years, so this may be longer): a record very few companies hold.
- **Dividend growth (5 yr): 5.5%/yr** (1-yr 4.9%). The dividend has grown 5.5% a year over five years.

## Analyst view
- **Analyst consensus: strong_buy** (15 analysts). 15 analysts cover West Pharmaceutical Services Inc.; the consensus is strong_buy, with an average price target of $404.73 (+19% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 37.8%** (YTD 23.8%, 3-mo 8.2%). The shares are up 37.8% over twelve months including dividends.
- **From 52-week high: -11.9%** (51.9% above the low). Trading 12% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 43**. An RSI of 43 is neutral.
- **Beta (1 yr): 0.66** (volatility 34%). Beta of 0.66 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=WST · Page: https://foliofundamentals.com/stocks/wst

Not investment advice.